Kiadis Pharma reports €1.1M loss for 2016

Kiadis Pharma, a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, has reported its audited annual results for the year ended December 31, 2016.

The company has reported loss of €1.1 million for the period. The company has recorded slight increase of loss comparing the last year when it reported €1.4 million.

Commenting on the annual results, Manfred Rüdiger, CEO of Kiadis Pharma, said: “We have continued to make good progress with our lead product ATIR101 during 2016. The statistically significant clinical data from our CR-AIR-007 Phase II trial shows substantially improved benefits on Overall Survival and Graft-versus-Host and Relapse-free Survival (GRFS), which exceeded our expectations. We have continued to maintain a close relationship with EMA and based on our Phase II clinical data, our previously obtained ATMP certificate for manufacturing/quality and non-clinical data, as well as our recently accepted Pediatric Investigational Plan, we are now in the final stages of preparing our application dossier for submission to EMA for marketing authorization in Europe. In addition, we have further strengthened the Company and the teams at all levels within the organization.”